GO:0014732 skeletal muscle atrophy: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014732 skeletal muscle atrophy is a biological process defined by decreased protein content, fiber diameter, force production and fatigue resistance in skeletal muscle in response to starvation, aging, disuse and disease.
• The process is driven by a shift in protein balance toward degradation, involving the ubiquitin-proteasome system, autophagy and apoptosis, and is opposed by IGF-1/Akt/mTOR signaling.
• Immobilisation and disuse trigger rapid atrophy in humans, with measurable loss of muscle mass and strength within days to weeks.
• Aging-related sarcopenia and metabolic conditions such as obesity and type-2 diabetes are strongly associated with skeletal muscle atrophy and dysfunction.
• Epigenetic mechanisms, including DNA methylation, histone modifications and non-coding RNAs, contribute to the regulation of atrophy-related gene expression.
• Key genes and pathways include FOXO transcription factors, MuRF1 (TRIM63), Atrogin-1 (FBXO32), myostatin (MSTN), IGF-1, and autophagy-related genes, which are prime targets for CRISPR-based functional studies.
Description
Skeletal muscle atrophy (GO:0014732) is a biological process occurring in skeletal muscle that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse. It represents a major clinical and socioeconomic burden because loss of muscle mass and strength contributes to frailty, metabolic dysfunction and increased mortality in multiple disease states. Understanding the molecular and cellular mechanisms of skeletal muscle atrophy is therefore essential for developing targeted therapies and for identifying robust biomarkers. Recent reviews have consolidated evidence that atrophy is not a single uniform process but a convergence of multiple catabolic pathways, including the ubiquitin-proteasome system, autophagy, apoptosis and mitochondrial dysfunction, which are differentially activated depending on the trigger. Human studies of immobilisation-induced atrophy have provided mechanistic insights into the time course of muscle loss and the molecular adaptations that occur during disuse and recovery. In parallel, aging-related muscle atrophy (sarcopenia) and metabolic conditions such as obesity and type-2 diabetes have been linked to specific myocellular mechanisms that impair muscle protein synthesis and enhance degradation. This article synthesizes the current understanding of GO:0014732, covering its definition, core mechanisms, key genes, disease relevance, and the research methods and CRISPR models used to study it.
skeletal muscle atrophy At A Glance
| GO ID | GO:0014732 |
|---|---|
| GO term | skeletal muscle atrophy |
| Ontology | biological_process |
| Synonym | None |
| Definition | A process, occurring in skeletal muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse. |
| Major function | Mediates muscle wasting in response to catabolic stimuli, affecting muscle mass, strength and metabolic homeostasis. |
| Key triggers | Starvation, aging, disuse/immobilisation, metabolic disorders, and disease states. |
| Core pathways | Ubiquitin-proteasome system, autophagy, apoptosis, IGF-1/Akt/mTOR signaling, and epigenetic regulation. |
| Research relevance | Target for therapeutic intervention in sarcopenia, cachexia, and metabolic disease; model for studying protein turnover and gene function. |
What Is GO:0014732?
GO:0014732 skeletal muscle atrophy is defined as a process, occurring in skeletal muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse. In simpler terms, it is the shrinking and weakening of skeletal muscle due to an imbalance between protein synthesis and degradation, triggered by diverse physiological and pathological stimuli.
Why Is skeletal muscle atrophy Important in Cell Biology?
Skeletal muscle atrophy is critically important because it affects millions of individuals worldwide and is associated with increased morbidity and mortality in conditions ranging from aging and immobilisation to cancer cachexia and metabolic disorders. Loss of muscle mass and function impairs mobility, increases fall risk, and reduces quality of life, while also exacerbating metabolic dysfunction through reduced glucose disposal. Understanding the molecular drivers of atrophy is essential for developing effective prevention and treatment strategies, and for identifying biomarkers that can guide clinical decision-making.
• Skeletal muscle atrophy is a hallmark of aging (sarcopenia) and contributes to frailty and loss of independence.
• Disuse-induced atrophy occurs rapidly during immobilisation, bed rest, and spaceflight, and is a major rehabilitation challenge.
• Metabolic conditions such as obesity and type-2 diabetes are associated with skeletal muscle atrophy and dysfunction, linking muscle wasting to systemic metabolism.
• Cancer cachexia and chronic inflammatory diseases involve skeletal muscle atrophy, worsening prognosis and treatment tolerance.
• The ubiquitin-proteasome system and autophagy are central catabolic pathways that are activated during atrophy and represent therapeutic targets.
• IGF-1/Akt/mTOR signaling opposes atrophy by promoting protein synthesis and inhibiting degradation, making it a key regulatory axis.
• Epigenetic modifications, including DNA methylation and histone acetylation, modulate atrophy-related gene expression and offer new intervention points.
• Skeletal muscle atrophy research informs the development of exercise mimetics, nutritional interventions, and pharmacological agents.
• Animal and cell models of atrophy are essential for dissecting gene function and for preclinical testing of candidate therapies.
• CRISPR-based gene editing enables precise manipulation of atrophy-related genes to establish causality and validate drug targets.
What Happens During skeletal muscle atrophy?
Initiation by catabolic stimuli
In simple terms: Atrophy starts when the body receives signals that tell muscles to break down instead of build up.
Skeletal muscle atrophy is initiated by diverse catabolic stimuli, including starvation, disuse, aging, and systemic diseases such as cancer and diabetes. These triggers activate intracellular signaling cascades that shift the balance from protein synthesis to protein degradation. For example, immobilisation rapidly induces a catabolic state in human muscle, characterized by decreased protein synthesis and increased proteolysis. In aging, a combination of anabolic resistance and chronic low-grade inflammation contributes to progressive muscle loss. Metabolic conditions such as obesity and type-2 diabetes mellitus are associated with myocellular mechanisms that impair muscle function and promote atrophy.
Activation of proteolytic systems
In simple terms: The cell turns on its recycling and disposal systems to break down muscle proteins.
A central event in skeletal muscle atrophy is the activation of proteolytic systems, primarily the ubiquitin-proteasome system and autophagy. The ubiquitin-proteasome system tags proteins with ubiquitin for degradation by the proteasome, and key E3 ubiquitin ligases such as MuRF1 (TRIM63) and Atrogin-1 (FBXO32) are upregulated in atrophic muscle. Autophagy, a lysosomal degradation pathway, is also induced during atrophy and contributes to the breakdown of organelles and proteins. Apoptosis, or programmed cell death, can further exacerbate muscle loss by reducing myonuclear number. These pathways are tightly regulated by transcription factors such as FOXO family members, which drive the expression of atrophy-related genes.
Suppression of protein synthesis
In simple terms: Muscle-building signals are turned down, so new proteins are not made fast enough to replace those being lost.
In parallel with increased degradation, skeletal muscle atrophy involves suppression of protein synthesis. The IGF-1/Akt/mTOR signaling pathway is a major regulator of muscle protein synthesis and hypertrophy, and its inhibition leads to reduced translation and increased atrophy. Akt phosphorylates and inhibits FOXO transcription factors, preventing their nuclear translocation and the induction of atrophy-related genes such as MuRF1 and Atrogin-1. During atrophy, reduced IGF-1 signaling or increased expression of negative regulators such as myostatin can lead to Akt inhibition and subsequent activation of FOXO-dependent catabolic programs. This dual effect on synthesis and degradation amplifies muscle loss.
Structural and functional remodeling
In simple terms: Muscle fibers shrink and weaken, changing the overall structure and performance of the muscle.
As atrophy progresses, skeletal muscle undergoes structural and functional remodeling, including a decrease in fiber diameter, loss of myofibrillar proteins, and reduced force production and fatigue resistance. These changes are accompanied by alterations in mitochondrial function and metabolic capacity, which further impair muscle performance. In aging, a preferential loss of fast-twitch fibers is often observed, contributing to reduced power output. Human studies of immobilisation have shown that these structural changes occur within days and can be partially reversed with rehabilitation, although recovery may be incomplete. The extent of remodeling depends on the duration and severity of the catabolic stimulus.
Epigenetic and transcriptional regulation
In simple terms: The cell's instruction manual is chemically modified, changing which genes are turned on or off during atrophy.
Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, play a critical role in regulating the expression of atrophy-related genes. These modifications can alter chromatin accessibility and transcription factor binding, thereby influencing the activation of catabolic pathways. For example, changes in histone acetylation and methylation have been linked to the regulation of FOXO targets and other atrophy genes. Non-coding RNAs, such as microRNAs and long non-coding RNAs, can modulate gene expression post-transcriptionally and have been implicated in muscle wasting. Understanding these epigenetic controls provides additional layers for therapeutic intervention.
Key Genes Involved in GO:0014732 skeletal muscle atrophy
The following genes and proteins are central to the regulation and execution of skeletal muscle atrophy, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FOXO1 | Transcription factor that drives expression of atrophy-related genes | Key mediator of catabolic signaling; target for CRISPR knockout to assess atrophy |
| FOXO3 | Transcription factor involved in autophagy and proteasome activation | Regulates muscle wasting; knockout models show reduced atrophy |
| TRIM63 (MuRF1) | E3 ubiquitin ligase that targets myofibrillar proteins for degradation | Biomarker of atrophy; knockout preserves muscle mass |
| FBXO32 (Atrogin-1) | E3 ubiquitin ligase that promotes protein degradation | Upregulated in multiple atrophy models; therapeutic target |
| MSTN (Myostatin) | Negative regulator of muscle growth | Inhibition increases muscle mass; knockout and knock-in models available |
| IGF1 | Growth factor that activates Akt/mTOR and promotes hypertrophy | Opposes atrophy; overexpression models used to study protection |
| AKT1 | Kinase that inhibits FOXO and activates mTOR | Central node in hypertrophy signaling; knockout causes atrophy |
| MTOR | Kinase that promotes protein synthesis | Target of rapamycin; inhibition induces atrophy |
| FOXO4 | Transcription factor contributing to muscle atrophy | Less studied but may compensate for FOXO1/3 |
| BNIP3 | Autophagy-related protein involved in mitophagy | Mediates mitochondrial clearance during atrophy |
| MAP1LC3B (LC3B) | Autophagosome marker | Used to monitor autophagy flux in atrophy models |
| ATG5 | Essential for autophagosome formation | Knockout blocks autophagy and affects atrophy |
| ATG7 | Essential for autophagy | Conditional knockout models reveal role in muscle mass regulation |
| CASP3 | Executioner caspase in apoptosis | Contributes to myonuclear loss during atrophy |
| CASP9 | Initiator caspase in intrinsic apoptosis | Activated in atrophic muscle |
| NFKB1 | Transcription factor that promotes catabolic signaling | Inflammation-induced atrophy; knockout reduces wasting |
| SMAD2/3 | Mediators of myostatin/TGF-beta signaling | Phosphorylated during atrophy; inhibit Akt |
| PRKAA1 (AMPK) | Energy sensor that can activate catabolic pathways | Links metabolic stress to atrophy |
How Is skeletal muscle atrophy Regulated?
Skeletal muscle atrophy is regulated by a complex network of signaling pathways and transcription factors. The IGF-1/Akt/mTOR axis is a major anabolic pathway that suppresses atrophy by promoting protein synthesis and inhibiting FOXO-mediated transcription. Conversely, catabolic stimuli such as myostatin, inflammatory cytokines, and glucocorticoids activate signaling cascades that inhibit Akt and activate FOXO, leading to increased expression of MuRF1 and Atrogin-1. AMPK, an energy sensor, can also modulate atrophy by influencing protein synthesis and degradation in response to metabolic stress. Epigenetic regulators, including histone deacetylases and DNA methyltransferases, further fine-tune the expression of atrophy-related genes. Additionally, autophagy is regulated by nutrient-sensing pathways such as mTOR and AMPK, which control the activity of ULK1 and other autophagy proteins. The integration of these signals determines the rate and extent of muscle loss.
skeletal muscle atrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FOXO1 | Sarcopenia, cachexia | Knockout and point-mutation models to assess atrophy resistance |
| TRIM63 (MuRF1) | Disuse atrophy, cachexia | Knockout mice and cell lines to study muscle preservation |
| FBXO32 (Atrogin-1) | Multiple atrophy conditions | Knockout and overexpression models to dissect degradation pathways |
| MSTN | Muscle wasting, sarcopenia | Knockout and knock-in models to enhance muscle mass |
| IGF1 | Age-related muscle loss | Overexpression and knock-in models to study hypertrophy |
Sarcopenia and aging
Aging is associated with a progressive loss of skeletal muscle mass and function, known as sarcopenia, which is a major cause of frailty and disability in older adults. Human skeletal muscle-specific atrophy with aging involves multifactorial mechanisms, including anabolic resistance, mitochondrial dysfunction, and chronic inflammation. The process is characterized by a decrease in fiber diameter, particularly of fast-twitch fibers, and reduced force production. Research into sarcopenia aims to identify molecular targets that can slow or reverse age-related muscle loss, with IGF-1 signaling and epigenetic regulators being prominent areas of investigation.
Disuse and immobilisation
Disuse-induced skeletal muscle atrophy occurs during immobilisation, bed rest, limb casting, and spaceflight, and is a significant clinical problem. Human studies have provided mechanistic insights into the time course of atrophy, showing rapid loss of muscle mass and strength within days of immobilisation. The molecular mechanisms involve decreased protein synthesis and increased proteolysis, with upregulation of MuRF1 and Atrogin-1. Prevention and recovery strategies include early mobilization, electrical stimulation, and nutritional interventions, but complete recovery may be incomplete. Understanding these mechanisms is essential for developing effective countermeasures.
Metabolic conditions: obesity and type-2 diabetes
Obesity and type-2 diabetes mellitus are associated with skeletal muscle atrophy and dysfunction, contributing to impaired glucose homeostasis and increased morbidity. Myocellular mechanisms involved include lipotoxicity, inflammation, mitochondrial dysfunction, and altered protein turnover. These conditions can exacerbate muscle loss through insulin resistance and impaired anabolic signaling. Research in this area focuses on identifying molecular links between metabolic dysregulation and muscle atrophy, with potential therapeutic targets including AMPK and inflammatory pathways.
Cancer cachexia and chronic disease
Skeletal muscle atrophy is a hallmark of cancer cachexia and other chronic diseases, contributing to poor prognosis and reduced quality of life. The mechanisms involve systemic inflammation, increased energy expenditure, and activation of catabolic pathways in muscle. Pro-inflammatory cytokines such as TNF-alpha and IL-6 activate NF-kB and STAT3, which promote atrophy-related gene expression. Targeting these pathways is a major focus of therapeutic development, and CRISPR models are used to dissect the contribution of specific genes.
From skeletal muscle atrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FOXO1 protect against disuse atrophy? | FOXO1 knockout mouse or CRISPR knockout in C2C12 myotubes |
| What is the role of MuRF1 in protein degradation? | TRIM63 knockout and point-mutation models |
| Can IGF-1 overexpression prevent sarcopenia? | IGF1 knock-in or overexpression mouse models |
| How does myostatin inhibition affect muscle mass? | MSTN knockout and knock-in models |
| What is the contribution of autophagy to atrophy? | ATG5 or ATG7 conditional knockout models |
| How do epigenetic modifiers regulate atrophy genes? | CRISPR knockout of DNMTs or HDACs in muscle cells |
How to Study the skeletal muscle atrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify atrophy-related genes and pathways |
| Proteomics | Protein abundance and modifications | Quantify loss of myofibrillar proteins |
| Stable isotope labeling | Protein synthesis and degradation rates | Assess turnover in atrophy models |
| Histology/immunofluorescence | Fiber size, type, and myonuclear number | Confirm atrophy phenotype |
| Electron microscopy | Ultrastructure and organelle integrity | Assess mitochondrial and sarcomere changes |
| Grip strength test | Muscle force in vivo | Functional assessment in mice |
| Dynamometry | Muscle strength in humans | Clinical studies of disuse atrophy |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
Transcriptomic profiling (RNA-seq)
RNA sequencing is widely used to identify global changes in gene expression during skeletal muscle atrophy. This method allows researchers to detect upregulation of atrophy-related genes such as TRIM63 and FBXO32, as well as changes in non-coding RNAs. Comparative transcriptomics between atrophic and control muscle can reveal novel pathways and biomarkers. Integration with epigenetic data can provide insights into regulatory mechanisms.
Proteomics and protein turnover assays
Proteomic approaches, including mass spectrometry-based quantification, are essential for measuring changes in protein abundance and post-translational modifications during atrophy. Protein turnover can be assessed using stable isotope labeling to measure synthesis and degradation rates. These methods help identify specific proteins that are lost or degraded and can validate targets identified by transcriptomics. They are also useful for assessing the efficacy of interventions.
Imaging and histology
Histological and imaging techniques, such as immunofluorescence and electron microscopy, are used to assess fiber cross-sectional area, fiber type composition, and myonuclear number. These methods provide direct evidence of atrophy and can be combined with molecular markers to study specific pathways. Non-invasive imaging modalities like MRI and DEXA are used in human studies to quantify muscle mass.
Functional assays
Functional assays, including grip strength and treadmill tests in animal models, and dynamometry in humans, measure force production and fatigue resistance. These assays are critical for linking molecular changes to physiological outcomes. In vitro, electrical stimulation of myotubes can be used to assess contractile function. Combining functional data with molecular analyses provides a comprehensive understanding of atrophy.
How CRISPR Can Be Used to Study GO:0014732 skeletal muscle atrophy
Knockout
CRISPR knockout is used to completely ablate genes of interest to determine their necessity in skeletal muscle atrophy. For example, knocking out TRIM63 or FBXO32 in mice or C2C12 cells can reveal whether these E3 ligases are required for muscle loss. Knockout of FOXO transcription factors can test their role in catabolic gene induction. These models are essential for establishing causality and for identifying potential therapeutic targets.
Point Mutation
Point mutations can be introduced to study specific amino acid residues or phosphorylation sites that regulate protein function. For instance, mutating Akt phosphorylation sites on FOXO can prevent its inhibition and alter atrophy signaling. Point mutations in ubiquitin ligases can disrupt substrate recognition without affecting overall protein stability. These models provide fine-grained mechanistic insights.
Knock-in
Knock-in models allow the introduction of reporter tags or human disease variants into the endogenous locus. Tagging endogenous MuRF1 or Atrogin-1 with fluorescent proteins enables real-time monitoring of their expression during atrophy. Knock-in of human myostatin variants can model disease-associated mutations. These models are valuable for studying gene regulation and for drug screening.
Overexpression
Overexpression of genes such as IGF1 or dominant-negative FOXO can be achieved via CRISPR-mediated knock-in of a strong promoter or by using viral vectors. Overexpression models are used to test whether a gene is sufficient to induce hypertrophy or protect against atrophy. For example, IGF-1 overexpression in muscle prevents age-related atrophy. These models complement knockout studies.
How EDITGENE Supports skeletal muscle atrophy Research
Researchers studying skeletal muscle atrophy-related genes often need to determine whether a candidate gene is causally involved in the process or is merely a bystander. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides a comprehensive suite of services to support such studies, from cell line generation to library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for skeletal muscle atrophy research.
Frequently Asked Questions About skeletal muscle atrophy
What is GO:0014732 skeletal muscle atrophy?
GO:0014732 is a Gene Ontology biological process term defined as a process occurring in skeletal muscle characterized by decreased protein content, fiber diameter, force production and fatigue resistance in response to conditions such as starvation, aging and disuse.
What genes are involved in skeletal muscle atrophy?
Key genes include FOXO1, FOXO3, TRIM63 (MuRF1), FBXO32 (Atrogin-1), MSTN (myostatin), IGF1, AKT1, MTOR, and autophagy-related genes such as ATG5 and ATG7.
What causes skeletal muscle atrophy?
Causes include starvation, aging, disuse/immobilisation, metabolic disorders such as obesity and type-2 diabetes, cancer cachexia, and chronic inflammatory diseases.
How is skeletal muscle atrophy measured in research?
It is measured by fiber cross-sectional area, muscle mass, force production, fatigue resistance, and molecular markers such as MuRF1 and Atrogin-1 expression.
What signaling pathways regulate skeletal muscle atrophy?
The IGF-1/Akt/mTOR pathway promotes muscle growth and inhibits atrophy, while FOXO transcription factors, myostatin, and inflammatory signaling promote catabolism.
What is the role of autophagy in skeletal muscle atrophy?
Autophagy is a lysosomal degradation pathway that is activated during atrophy and contributes to the breakdown of proteins and organelles; it is regulated by ATG genes and nutrient-sensing pathways.
How does aging affect skeletal muscle atrophy?
Aging leads to sarcopenia, characterized by progressive loss of muscle mass and strength due to anabolic resistance, mitochondrial dysfunction, and chronic inflammation.
Can skeletal muscle atrophy be reversed?
Atrophy can be partially reversed with rehabilitation, nutritional interventions, and exercise, but recovery may be incomplete depending on the duration and severity of the catabolic stimulus.
What CRISPR models are used to study skeletal muscle atrophy?
Knockout, point mutation, knock-in, and overexpression models in muscle cell lines and mice are used to dissect gene function and validate therapeutic targets.
Why is skeletal muscle atrophy important in metabolic disease?
Obesity and type-2 diabetes are associated with muscle atrophy and dysfunction, which exacerbates insulin resistance and metabolic dysregulation.
Conclusion
Skeletal muscle atrophy (GO:0014732) is a complex biological process driven by an imbalance between protein synthesis and degradation, with profound implications for aging, disuse, metabolic disease, and cancer cachexia. The identification of key genes and pathways, including FOXO, MuRF1, Atrogin-1, IGF-1/Akt/mTOR, and autophagy regulators, has provided a framework for understanding the molecular basis of muscle wasting. Continued research using advanced CRISPR models and multi-omics approaches will be essential for developing effective therapies to prevent or reverse atrophy.
References
- 1. Yin L et al.. 2021. Skeletal muscle atrophy: From mechanisms to treatments.. Pharmacol Res 172:105807 PMID: 34389456
- 2. Yoshida T et al.. 2020. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.. Cells 9(9) PMID: 32858949
- 3. Deane CS et al.. 2024. Skeletal muscle immobilisation-induced atrophy: mechanistic insights from human studies.. Clin Sci (Lond) 138(12):741-756 PMID: 38895777
- 4. Naruse M et al.. 2023. Human skeletal muscle-specific atrophy with aging: a comprehensive review.. J Appl Physiol (1985) 134(4):900-914 PMID: 36825643
- 5. Nunes EA et al.. 2022. Disuse-induced skeletal muscle atrophy in disease and nondisease states in humans: mechanisms, prevention, and recovery strategies.. Am J Physiol Cell Physiol 322(6):C1068-C1084 PMID: 35476500
- 6. Liang W et al.. 2024. Epigenetic control of skeletal muscle atrophy.. Cell Mol Biol Lett 29(1):99 PMID: 38978023
- 7. Jun L et al.. 2023. Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions.. Int J Mol Sci 24(3) PMID: 36769296
- 8. Castillo ÍMP et al.. 2025. Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved.. Rev Endocr Metab Disord 26(5):815-836 PMID: 40064750
